Literature DB >> 12629621

Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening.

Judith H Maselli1, Marci K Sontag, Jill M Norris, Todd MacKenzie, Jeff S Wagener, Frank J Accurso.   

Abstract

The objective of this study was to identify risk factors for initial detection of Pseudomonas aeruginosa (P. aeruginosa) in children with cystic fibrosis (CF) identified by newborn screening. Life history data on 180 patients, collected prospectively in a follow-up study of infants and children diagnosed with CF, were examined for factors associated with the initial detection of P. aeruginosa ascertained by oropharyngeal cultures. Univariate and multivariate Cox proportional hazards regression analyses were used to assess the effect of baseline and time-varying covariates on age at first positive culture for P. aeruginosa. Seventy-nine patients (44%) had at least one culture positive for P. aeruginosa during the study. The median age of detection was 8.1 years (95% CI, 7.0, 10.0). Median length of follow-up was 4.1 years, ranging from 0.2-15.5 years. Multivariate Cox regression analysis identified female gender (RR, 1.85; 95% CI, 1.14, 3.01), the DeltaF508 homozygous genotype (RR, 2.23; 95% CI, 1.30, 3.80), and S. aureus isolations (RR, 1.30; 95% CI, 1.11, 1.52) to be independently associated with acquisition of P. aeruginosa. Other marginally independent associations were found with days hospitalized and increased height. We conclude that female gender, homozygous DeltaF508 mutation, and S. aureus isolations are important risk factors for early P. aeruginosa detection in children with CF identified through newborn screening. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12629621     DOI: 10.1002/ppul.10230

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  21 in total

1.  Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Deanna M Green; J Michael Collaco; Kathryn E McDougal; Kathleen M Naughton; Scott M Blackman; Garry R Cutting
Journal:  J Pediatr       Date:  2012-02-23       Impact factor: 4.406

2.  Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

Authors:  Jerry A Nick; Cathy S Chacon; Sara J Brayshaw; Marion C Jones; Christine M Barboa; Connie G St Clair; Robert L Young; David P Nichols; Jennifer S Janssen; Gwen A Huitt; Michael D Iseman; Charles L Daley; Jennifer L Taylor-Cousar; Frank J Accurso; Milene T Saavedra; Marci K Sontag
Journal:  Am J Respir Crit Care Med       Date:  2010-05-06       Impact factor: 21.405

Review 3.  Cystic fibrosis chronic rhinosinusitis: a comprehensive review.

Authors:  Mohamad R Chaaban; Alexandra Kejner; Steven M Rowe; Bradford A Woodworth
Journal:  Am J Rhinol Allergy       Date:  2013 Sep-Oct       Impact factor: 2.467

4.  Sex and Gender Differences in Lung Disease.

Authors:  Patricia Silveyra; Nathalie Fuentes; Daniel Enrique Rodriguez Bauza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease.

Authors:  Jessica E Pittman; Elizabeth H Calloway; Michelle Kiser; John Yeatts; Stephanie D Davis; Mitchell L Drumm; Michael S Schechter; Margaret W Leigh; Mary Emond; Annelies Van Rie; Michael R Knowles
Journal:  Pediatr Pulmonol       Date:  2010-12-30

6.  Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort.

Authors:  Margaret Rosenfeld; Julia Emerson; Sharon McNamara; Valeria Thompson; Bonnie W Ramsey; Wayne Morgan; Ronald L Gibson
Journal:  J Cyst Fibros       Date:  2012-05-01       Impact factor: 5.482

7.  Gender differences in outcomes of patients with cystic fibrosis.

Authors:  Cayce L Harness-Brumley; Alan C Elliott; Daniel B Rosenbluth; Deepa Raghavan; Raksha Jain
Journal:  J Womens Health (Larchmt)       Date:  2014-12       Impact factor: 2.681

8.  Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

Authors:  Hara Levy; Leslie A Kalish; Carolyn L Cannon; K Christopher García; Craig Gerard; Don Goldmann; Gerald B Pier; Scott T Weiss; A A Colin
Journal:  Pediatr Pulmonol       Date:  2008-05

9.  Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.

Authors:  Miriam M Treggiari; Margaret Rosenfeld; Nicole Mayer-Hamblett; George Retsch-Bogart; Ronald L Gibson; Judy Williams; Julia Emerson; Richard A Kronmal; Bonnie W Ramsey
Journal:  Contemp Clin Trials       Date:  2009-01-15       Impact factor: 2.226

10.  IL1B polymorphisms modulate cystic fibrosis lung disease.

Authors:  Hara Levy; Amy Murphy; Fei Zou; Craig Gerard; Barbara Klanderman; Brooke Schuemann; Ross Lazarus; K Christopher García; Juan C Celedón; Mitch Drumm; Mary Dahmer; Michael Quasney; Kaitlyn Schneck; Melissa Reske; Michael R Knowles; Gerald B Pier; Christoph Lange; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.